Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease

Standard

Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. / Döcke, S; Lock, J F; Birkenfeld, A L; Hoppe, S; Lieske, S; Rieger, A; Raschzok, N; Sauer, I M; Florian, S; Osterhoff, M A; Heller, R; Herrmann, K; Lindenmüller, S; Horn, P; Bauer, M; Weickert, M O; Neuhaus, P; Stockmann, M; Möhlig, M; Pfeiffer, A F H; von Loeffelholz, C.

In: EUR J ENDOCRINOL, Vol. 169, No. 5, 11.2013, p. 547-57.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Döcke, S, Lock, JF, Birkenfeld, AL, Hoppe, S, Lieske, S, Rieger, A, Raschzok, N, Sauer, IM, Florian, S, Osterhoff, MA, Heller, R, Herrmann, K, Lindenmüller, S, Horn, P, Bauer, M, Weickert, MO, Neuhaus, P, Stockmann, M, Möhlig, M, Pfeiffer, AFH & von Loeffelholz, C 2013, 'Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease', EUR J ENDOCRINOL, vol. 169, no. 5, pp. 547-57. https://doi.org/10.1530/EJE-13-0112

APA

Döcke, S., Lock, J. F., Birkenfeld, A. L., Hoppe, S., Lieske, S., Rieger, A., Raschzok, N., Sauer, I. M., Florian, S., Osterhoff, M. A., Heller, R., Herrmann, K., Lindenmüller, S., Horn, P., Bauer, M., Weickert, M. O., Neuhaus, P., Stockmann, M., Möhlig, M., ... von Loeffelholz, C. (2013). Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. EUR J ENDOCRINOL, 169(5), 547-57. https://doi.org/10.1530/EJE-13-0112

Vancouver

Döcke S, Lock JF, Birkenfeld AL, Hoppe S, Lieske S, Rieger A et al. Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. EUR J ENDOCRINOL. 2013 Nov;169(5):547-57. https://doi.org/10.1530/EJE-13-0112

Bibtex

@article{db7bf00a8b5149a983a53458729ea988,
title = "Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease",
abstract = "OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective.DESIGN: This study was cross-sectional and experimental in design.METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)).RESULTS: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05).CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.",
keywords = "Aged, Body Weight, Cells, Cultured, Chemokines, Cross-Sectional Studies, Fatty Liver, Female, Humans, Intercellular Signaling Peptides and Proteins, Linear Models, Liver, Liver Cirrhosis, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, RNA, Messenger, Real-Time Polymerase Chain Reaction, Receptors, Chemokine",
author = "S D{\"o}cke and Lock, {J F} and Birkenfeld, {A L} and S Hoppe and S Lieske and A Rieger and N Raschzok and Sauer, {I M} and S Florian and Osterhoff, {M A} and R Heller and K Herrmann and S Lindenm{\"u}ller and P Horn and M Bauer and Weickert, {M O} and P Neuhaus and M Stockmann and M M{\"o}hlig and Pfeiffer, {A F H} and {von Loeffelholz}, C",
year = "2013",
month = nov,
doi = "10.1530/EJE-13-0112",
language = "English",
volume = "169",
pages = "547--57",
journal = "EUR J ENDOCRINOL",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease

AU - Döcke, S

AU - Lock, J F

AU - Birkenfeld, A L

AU - Hoppe, S

AU - Lieske, S

AU - Rieger, A

AU - Raschzok, N

AU - Sauer, I M

AU - Florian, S

AU - Osterhoff, M A

AU - Heller, R

AU - Herrmann, K

AU - Lindenmüller, S

AU - Horn, P

AU - Bauer, M

AU - Weickert, M O

AU - Neuhaus, P

AU - Stockmann, M

AU - Möhlig, M

AU - Pfeiffer, A F H

AU - von Loeffelholz, C

PY - 2013/11

Y1 - 2013/11

N2 - OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective.DESIGN: This study was cross-sectional and experimental in design.METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)).RESULTS: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05).CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.

AB - OBJECTIVE: Adipose tissue-derived factors link non-alcoholic fatty liver disease (NAFLD) with obesity, which has also been reported for circulating chemerin. On the other hand, hepatic chemerin and chemokine-like receptor 1 (CMKLR1) mRNA expression has not yet been studied in an extensively characterized patient collective.DESIGN: This study was cross-sectional and experimental in design.METHODS: Liver tissue samples were harvested from 47 subjects and histologically examined according to the NAFLD activity score (NAS). The concentrations of chemerin and CMKLR1 were measured using semi-quantitative real-time PCR, and the concentration of serum chemerin was measured using ELISA. To evaluate potential effects of chemerin and CMKLR1, cultured primary human hepatocytes (PHHs) were exposed to selected metabolites known to play a role in NAFLD (insulin, glucagon, palmitoic acid, and interleukin-6 (IL6)).RESULTS: Chemerin and CMKLR1 mRNA levels were elevated in the human liver. Their expression was correlated with the NAS (R(2)=0.543; P<0.001 and R(2)=0.355; P=0.014 respectively) and was significantly elevated in patients with definite non-alcoholic steatohepatitis (NASH) (P<0.05 respectively). Linear regression analysis confirmed an independent association of liver fibrosis, steatosis, inflammation, and hepatocyte ballooning with hepatic chemerin mRNA expression (P<0.05 respectively). The expression of hepatic chemerin and CMKLR1 was correlated with the measures of obesity (P<0.05). The incubation of PHHs with IL6 significantly increased the expression of CMKLR1 mRNA (P=0.027), while that of chemerin remained unaffected (P>0.05). None of the other metabolites showed an influence (P>0.05).CONCLUSION: This is the first study to show that chemerin mRNA expression is significantly elevated in the liver of NASH patients and that CMKLR1 expression is upregulated in liver inflammation, whereby IL6 could play a causal role.

KW - Aged

KW - Body Weight

KW - Cells, Cultured

KW - Chemokines

KW - Cross-Sectional Studies

KW - Fatty Liver

KW - Female

KW - Humans

KW - Intercellular Signaling Peptides and Proteins

KW - Linear Models

KW - Liver

KW - Liver Cirrhosis

KW - Male

KW - Middle Aged

KW - Non-alcoholic Fatty Liver Disease

KW - RNA, Messenger

KW - Real-Time Polymerase Chain Reaction

KW - Receptors, Chemokine

U2 - 10.1530/EJE-13-0112

DO - 10.1530/EJE-13-0112

M3 - SCORING: Journal article

C2 - 23935128

VL - 169

SP - 547

EP - 557

JO - EUR J ENDOCRINOL

JF - EUR J ENDOCRINOL

SN - 0804-4643

IS - 5

ER -